Cipla gets 6 observations from USFDA for Goa facility
Drug Approval

Cipla gets 6 observations from USFDA for Goa facility

The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time

  • By IPP Bureau | June 24, 2024

USFDA has conducted an inspection at the Cipla Ltd's manufacturing facility in Goa, India from 10th - 21st June 2024.

On conclusion of the inspection, the company received 6 (six) inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International